Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
MK-677 is an oral, non-peptide ghrelin-receptor agonist that stimulates the pituitary's own pulsatile GH release rather than replacing GH directly. In the pivotal 2-year RCT in healthy older adults (Nass et al. 2008, Ann Intern Med, PMID 18981485), 25mg/day raised IGF-1 roughly 1.5-fold and modestly increased fat-free mass (+1.1kg vs placebo, driven largely by intracellular water) while also raising fasting glucose and HbA1c and reducing insulin sensitivity. Does not suppress testosterone and requires no PCT. Rated 4, consistent with the other GH secretagogues in this scale (CJC-1295, Ipamorelin, GHRP-2/6, tesamorelin), a genuine step up in GH/IGF-1 exposure beyond natural pulsatile release, but well below exogenous HGH or IGF-1 itself, and its real-world muscle-building effect is modest relative to its metabolic cost.
Overview
An oral ghrelin mimetic that stimulates GH pulses. Technically not a peptide but a non-peptide agonist of the ghrelin receptor that increases growth hormone and IGF-1 levels.
Important Warnings
- •Can significantly impair blood glucose - monitor regularly
- •Not suitable for diabetics or pre-diabetics
- •A 2-year RCT (Nass et al. 2008) found the fasting glucose/HbA1c increase and reduced insulin sensitivity persisted for the full study duration - this is not a short-term adaptation effect
Purpose & Use Cases
Increased IGF-1
Elevates IGF-1 levels for enhanced recovery and growth.
Improved Sleep
Significantly enhances sleep quality, particularly REM and deep sleep.
Appetite Stimulation
Dramatically increases appetite, useful for hardgainers.
Benefits
- Oral administration (no injections)
- Improved sleep quality
- Increased appetite
- Elevated IGF-1 levels
- Enhanced recovery
- Improved skin and hair
Good to Know
It is a ghrelin mimetic, not GH, and not a SARM
MK-677 does not add growth hormone. It activates the ghrelin receptor so your own pituitary releases GH in natural pulses. That is why it is oral, why it drives hunger (ghrelin is the hunger hormone), and why its IGF-1 bump is real but gentler than injectable HGH.
The blood-sugar cost is the real catch
The GH/IGF-1 rise reliably worsens insulin sensitivity and raises fasting glucose. This is the effect to actually manage, monitor glucose/HbA1c and use berberine, rather than the water retention or hunger, which are mostly cosmetic.
Not suppressive: no PCT, can run long
Unlike steroids or SARMs, MK-677 does not touch the HPTA, so no PCT is needed and it can run for extended periods (glucose permitting). Its most reliable benefits are deeper sleep and recovery, not muscle per se.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 12.5 – 12.5 mg/day |
| Intermediate | 12.5 – 25 mg/day |
| Advanced | 25 – 25 mg/day |
Can be run longer but 8-12 weeks is typical. Monitor blood glucose.
The often-cited ~4-6h plasma elimination half-life is derived from animal (canine) pharmacokinetic data rather than a confirmed human PK study; the GH/IGF-1 elevation itself lasts roughly 24h in humans with once-daily oral dosing (single-dose data).
Side Effects
Elevated Blood Glucose
very commonReliably impairs glucose tolerance and insulin sensitivity. In the 2-year RCT (Nass et al. 2008) fasting glucose rose ~5mg/dL (0.3mmol/L) and HbA1c by 0.2% at 25mg/day, with a significant decline in insulin sensitivity (QUICKI index); a 4-week dose-ranging study similarly found significant fasting-glucose increases at 25mg/day.
Low-carb diet; monitor fasting glucose; consider Berberine.
Water Retention
very commonMild, typically transient lower-extremity edema/bloating. In the 2-year RCT it occurred in 44% of MK-677 users vs 27% on placebo, described as mild and transient rather than severe.
Usually manageable; reduce dose if excessive.
Extreme Hunger
very commonSignificantly increased appetite, can make dieting difficult.
Time dosing for before bed to sleep through worst hunger.
Lethargy
commonSome users experience daytime sleepiness.
Take before bed; adjust timing if needed.
General Mitigation Strategies
Low-carb diet to manage blood glucose. Take before bed to minimize hunger issues. Monitor fasting glucose regularly. A home glucometer or CGM is the single most useful "support supplement". Track fasting glucose, fasting insulin/HOMA-IR and HbA1c, and add berberine (or discontinue) if numbers trend toward prediabetic.
Support Supplements
Ancillary supplements commonly run alongside MK-677 to manage side effects, support the target tissue, or fill nutrient demands it creates.
Berberine
KeyCounters the elevated fasting glucose and insulin resistance MK-677 causes (a GH effect). Acts as an AMPK activator with a "metformin-like" glucose-lowering profile.
- Dose
- 500mg, 2-3x daily (1,000-1,500mg/day total)
- Timing
- 15-30 min before carb-containing meals
- When
- The one genuinely evidence-based support for MK-677. Still monitor glucose/HbA1c: berberine blunts but does not eliminate the effect. Additive hypoglycemia risk with metformin/insulin; strong CYP3A4/P-gp inhibitor (interacts with statins and many drugs).
P5P (Vitamin B6)
Popularly recommended to "control prolactin and water retention" from MK-677.
- Dose
- 25-50mg/day if used
- Timing
- With food
- When
- Weak rationale: MK-677 does not reliably raise prolactin in clinical data, and B6's anti-edema evidence is PMS-specific. Largely optional/bro-science for this purpose. Avoid chronic high doses (>100-200mg/day): risk of sensory peripheral neuropathy.
Post Cycle Therapy (PCT)
Does not suppress testosterone. No PCT required.
How It Works
MK-677 mimics ghrelin and binds to ghrelin receptors in the brain, stimulating the pituitary to release growth hormone. Unlike injectable GH, it promotes natural pulsatile GH release patterns.
Fundamentals
Reference on the practices relevant to MK-677: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- MK-677 + SARMs - Enhanced recovery and growth
- MK-677 + Testosterone - Synergistic mass building
Legal Status
Research chemical, not for human consumption (USA).
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Ibutamoren (MK-677) is prohibited at all times under WADA category S2 as a growth hormone secretagogue.
References
- Nass et al. 2008: MK-677 2-year RCT in healthy older adults (Ann Intern Med, PMID 18981485)
- Chapman et al. 1996: MK-677 dose-ranging study (GH/IGF-1, glucose, cortisol, prolactin) in healthy elderly subjects (J Clin Endocrinol Metab, PMID 8954023)
- Ibutamoren (MK-677): ghrelin-receptor mechanism, pharmacokinetics and effects (Wikipedia)
- Berberine moderates glucose and lipid metabolism through multipathway mechanism (PMC2952334)